OTTAWA, ON, Nov. 19, 2024 /CNW/ - Tłegǫ́hłı̨ Got'įnę, Crown-Indigenous Relations and Northern Affairs Canada, and the Government of Northwest Territories Self-government agreements affirm Indigenous ...
On Monday, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback